Cited by 100Alzheimer's disease research and treatmentsMemory and Neural MechanismsDementia and Cognitive Impairment Research

Hippocampal Injections of Oligomeric Amyloid β-peptide (1–42) Induce Selective Working Memory Deficits and Long-lasting Alterations of ERK Signaling Pathway

Open access
Faucher, Pierre, Mons, Nicole, Micheau, Jacques, Louis, Caroline, Beracochea, Daniel J.·2016·Frontiers in Aging Neuroscience

Abstract

Increasing evidence suggests that abnormal brain accumulation of soluble rather than aggregated amyloid-β1-42 oligomers (Aβo(1-42)) plays a causal role in Alzheimer's disease (AD). However, as yet, animal's models of AD based on oligomeric amyloid-β1-42 injections in the brain have not investigated their long-lasting impacts on molecular and cognitive functions. In addition, the injections have been most often performed in ventricles, but not in the hippocampus, in spite of the fact that the hippocampus is importantly involved in memory processes and is strongly and precociously affected during the early stages of AD. Thus, in the present study, we investigated the long-lasting impacts of intra-hippocampal injections of oligomeric forms of Aβo(1-42) on working and spatial memory and on the related activation of ERK1/2. Indeed, the extracellular signal-regulated kinase (ERK) which is involved in memory function had been found to be activated by amyloid peptides. We found that repeated bilateral injections (1injection/day over 4 successive days) of oligomeric forms of Aβo(1-42) into the dorsal hippocampus lead to long-lasting impairments in two working memory tasks, these deficits being observed 7 days after the last injection, while spatial memory remained unaffected. Moreover, the working memory deficits were correlated with sustained impairments of ERK1/2 activation in the medial prefrontal cortex (mPFC) and the septum, two brain areas tightly connected with the hippocampus and involved in working memory. Thus, our study is first to evidence that sub-chronic injections of oligomeric forms of Aβo(1-42) into the dorsal hippocampus produces the main sign of cognitive impairments corresponding to the early stages of AD, via long-lasting alterations of an ERK/MAPK pathway in an interconnected brain networks.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fnagi.2015.00245

Cites

97 of 97 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intra-hippocampal injections of Aβ oligomers cause memory loss correlated with ERK1/2 pathway activation.

    “Similarly, intra-hippocampal injections of Aβ oligomers showed loss of memory, correlated with the ERK1/2 pathway activation, which is involved in memory function [145].”

    From Alzheimer's Disease: Treatment Strategies and Their Limitations. (2022) · cites this paper as [145]

    The Discussion reports that intra-hippocampal Aβ oligomer injections caused working-memory impairments associated with a blockade of test-induced ERK1/2 activation in specific brain structures. The claim captures the link to ERK1/2 signaling but omits the decisive direction: the observed change was impaired activation, not activation associated with memory loss. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 99 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Faucher, P., Mons, N., Micheau, J., Louis, C., & Beracochea, D. J.
Affiliations
  • Centre National de la Recherche Scientifique (FR)
  • Institut de Recherches Internationales Servier (France) (FR)
Venue
Frontiers in Aging Neuroscience
Published
2016-01-11
Volume
7
Pages
245-245
ISSN
1663-4365 (ISSN-L)
OpenAlex
W2238119500
Cited by
100
References
99
Citations by year
2026: 2 · 2025: 7 · 2024: 6 · 2023: 16 · 2022: 13 · 2021: 11 · 2020: 18 · 2019: 6 · 2018: 10 · 2017: 6 · 2016: 5
FWCI
7.25
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Aging Neuroscience (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Centre National de la Recherche Scientifique
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, hippocampus, working memory deficits, spatial memory, ERK signaling, MAPK signaling, medial prefrontal cortex, septum, intracerebral injection, early Alzheimer's disease, cognitive impairment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review